Form 4: Revolution Medicines Executive Stephen Michael Kelsey Executes Option and Sells Shares Under 10b5-1 Plan

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On July 15, 2024, Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, exercised stock options to acquire 16,667 shares of common stock at a price of $4.09 per share.
• Simultaneously, Kelsey sold a total of 16,667 shares of common stock in multiple transactions at prices ranging from $43.37 to $48.47 per share.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on March 15, 2024.
• Following these transactions, Kelsey directly owns 269,073 shares of Revolution Medicines common stock, which includes 95,476 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The use of a 10b5-1 trading plan suggests that the sales were pre-planned and not based on insider information at the time of the transactions.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan mitigates this concern.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The sale of shares under a 10b5-1 plan is a standard practice among executives at publicly traded companies, including those in the biotechnology sector like Amgen, Gilead Sciences, and Regeneron.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests that the sales were pre-planned and not based on any material non-public information.

Key Dates